Expert Interviews

The lymphoma expert offered highlights from the meeting, with hopes that more treatment options will be available for patients with lymphoma.

An expert panel reacts to polling data on choice of imaging modalities for patients with prostate patients after definitive therapy and share their insights about best practices.  

Dr. Rebecca Previs shares data on some exiting emerging therapies in the front line setting for patients with advanced ovarian cancer.

Raoul Concepcion, MD, presents the case of a 58-year-old man who had a radical prostatectomy 6 months prior and discusses how aspects of the case influence treatment selection. 

An expert in ovarian cancer describes how initial first line therapy impacts first line maintenance options.

Around the Practice: Metastatic Castrate Resistant Prostate Cancer

Around the Practice: High-Risk Renal Cell Carcinoma

CancerNetwork® spoke with Abdulraheem Yacoub, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how predictors of response to therapy may be just as important as the development of new therapies for advancing outcomes in myelofibrosis and myeloproliferative neoplasms.

Kim detailed the specifics of his research from the American Association for Cancer Research Annual Meeting 2021 focusing on novel therapies to target mutations and upstream or downstream pathways.

Marron detailed the research process for a phase 1 trial of PGV-001 presented virtually at the American Association for Cancer Research Annual Meeting 2021.

CancerNetwork® spoke with Vivek Subbiah, MD, during the virtual American Association for Cancer Research Annual Meeting 2021 to discuss the most important data to come out of the meeting regarding therapy for tumors harboring KRAS mutations.

CancerNetwork® spoke with Matthew D. Galsky, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss leading data to come out of the meeting and what it means for the future of cancer systemic therapy.

Dr. Rebecca Previs talks about when first line maintenance therapy is appropriate and which patients should be presented with this option.

Dr. Rebecca Previs discusses the role of PARP inhibitors in first line maintenance therapy in advanced ovarian cancer.

Experts in prostate cancer discuss considerations for initiating ADT therapy after definitive treatment in patients with prostate cancer in the context of biochemical recurrence. 

Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer. 

The lymphoma expert discussed how the addition of copanlisib to rituximab may add another treatment option for patients with relapsed indolent B-cell lymphomas.

During a Deep Dive segment of Medical World News®, CancerNetwork® sat down with Maurie Markman, MD, to discuss how lessons learned from the development of mRNA vaccines for COVID-19 can translate to cancer research.

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about her thoughts on the effect of the conference content across multidisciplinary specialties.

Marron discussed the primary objectives and early data from a phase 1 trial presented at the virtual AACR Annual Meeting regarding the neoantigen peptide vaccine, PGV-001.